Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience
- 7 August 2019
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (5) , e13043
Abstract
Nonmelanoma skin cancer is the most common malignant tumor in the fair skin population, with each year several millions of diagnosed cases. Their most common risk factors are fair skin, a history of excessive ultraviolet light exposure, chronic inflammatory skin conditions, exposure to radiation, and contact with arsenic. Certain drugs can also be associated with a higher risk of nonmelanoma skin cancer. These include hydroxyurea, which acts as a metabolic inhibitor of ribonucleotide reductase and a potent nonalkylating myelosuppressive agent. It is used for the treatment of various myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia. Several publications describe an increased occurrence of skin manifestations following hydroxyurea treatment. A growing body of evidence indicates a possible role of hydroxyurea in skin cancer progression. In this review article, we summarize some relevant observations about the association of hydroxyurea and skin cancer, and we describe our own clinical experiences to provide up to date recommendations about the care of patients on hydroxyurea therapy.Keywords
This publication has 24 references indexed in Scilit:
- Chemoprevention of Nonmelanoma Skin CancerFacial Plastic Surgery, 2013
- Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPNAmerican Journal of Hematology, 2012
- A multidisciplinary team approach to hydroxyurea‐associated chronic wound with squamous cell carcinomaInternational Wound Journal, 2011
- Hydroxyurea-associated squamous dysplasia in a monozygotic twinJournal of the American Academy of Dermatology, 2011
- Efeitos colaterais cutâneos após uso prolongado de hidroxiuréia na Policitemia VeraAnais Brasileiros de Dermatologia, 2011
- Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applicationsMedical Hypotheses, 2011
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Oral squamous cell carcinoma during long-term treatment with hydroxyureaClinical and Experimental Dermatology, 2004
- The cutaneous side-effects of hydroxyureaClinical and Laboratory Haematology, 2000
- Effets secondaires cutanés de l'hydroxyurée : étude prospective de 26 patients consultant dans un service de dermatologieLa Revue de Médecine Interne, 2000